Enfortumab vedotin and pembrolizumab recommended for NHS Scotland

Second national grant strengthens company’s expanding global IP estate

Early safety and efficacy signals support move into repeat‑dose phase 2a trial

Partnership builds on existing collaboration and adds two new UCB‑nominated projects

Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device

Findings support once‑daily dosing and reinforce PALI‑2108’s potential

Study expands evaluation of survivin‑targeting vaccine

UK spin‑out speeds up development and reduces animal testing

Boehringer Ingelheim reports significant reductions in weight

Partnership to support selection of first neoantigen therapy candidate